INSIGHTS ON DRUG DEVELOPMENT
-
How Solid-State Characterization Shapes Drug Development
Mark Benger, Site Director at Cambrex Edinburgh, on solid-state characterization as an insurance policy — front-loaded work that quietly determines whether a program survives the jump from kilos to tonnes.
-
Working With Clients To Develop Manufacturing Processes
Greg Buenger, Group Leader of Chemical Development at Cambrex Charles City, on what it actually looks like when R&D hands a process to the plant — chemists on the floor for the first batch, advising operators and troubleshooting in real time.
-
Emerging Technologies In Reactor Design
Jillian Sheeran, Associate Director of Engineering at Snapdragon Chemistry, on how automation, feedback control, and machine learning are changing reactor design — with real-time monitoring that lets a process run continuously while the data comes to you.
-
How Do You Start Process Transfer For A New Client?
Anmaris Torres, Process Engineering Team Leader, on why a process transfer starts with a conversation across departments to figure out how to cut cycle time before commercial production begins.
-
Market Dynamics Related To The Development And Commercialization Of Peptides7/23/2026
Matt Bio, CSO of Cambrex and President of Snapdragon Chemistry, on the capacity bottleneck behind peptide shortages — and why moving from solid-phase to liquid-phase synthesis unlocks reactors already sitting idle around the world.
-
Cross-Site Work Within Cambrex's Network7/24/2026
Matthew Zart, Group Leader of Analytical Development, on what happens when a method arrives from another site — inheriting Phase II work from High Point and getting it commercial-ready for the QC lab.
-
How AI And Automation Are Impacting Process Development7/23/2026
David Ford, Senior Director of Chemistry at Snapdragon Chemistry, on the mountain of data behind every process development program — and why AI's real promise is surfacing the right piece of it at the moment a team needs to decide.
-
Approaching Process Validation During Tech Transfer To Commercial Manufacturing7/23/2026
Matthew Schiesher, Head of R&D at Cambrex Charles City, on validating processes under the clock — and how running multiple sites in parallel shortens the path to launch when patients are waiting.
-
How Biocatalysts Address Process Development Issues7/23/2026
Antje Gupta, General Manager of Cambrex IEP in Wiesbaden, on where biocatalysis outperforms conventional chemistry — matching enzyme classes to target conversions and production volumes to find the more scalable, more economical route.
DRUG DEVELOPMENT SOLUTIONS
-
MaxPeak™ Premier Columns utilize MaxPeak High Performance Surfaces that are designed to increase analyte recovery, sensitivity, and reproducibility by minimizing analyte/surface interactions that can lead to sample losses.
-
SimpleStep ELISA® kits are sandwich ELISA assays that we have developed to be as simple and effective as possible. Unlike traditional sandwich ELISAs, which take more than three hours to run, SimpleStep ELISA kits generate data in just 90 minutes without compromising performance, using only one wash step and recombinant antibodies for exceptional specificity.
-
Discover three solutions that provide the performance, reliability, and ease-of-use required for the most demanding applications in drug discovery, protein-protein interactions, structure-function characterization, and more.
-
Accelerate your path to market with integrated support to streamline processes, reduce delays, and deliver safe, user-friendly drug-delivery solutions.